12
IRUS Total
Downloads
  Altmetric

A micropillar array-based microfluidic chip for label-free separation of circulating tumor cells: the best micropillar geometry?

File Description SizeFormat 
1-s2.0-S2090123222001734-main.pdfPublished version4.02 MBAdobe PDFView/Open
Title: A micropillar array-based microfluidic chip for label-free separation of circulating tumor cells: the best micropillar geometry?
Authors: Rahmanian, M
Sartipzadeh Hematabad, O
Askari, E
Shokati, F
Bakhshi, A
Moghadam, S
Olfatbakhsh, A
Al Sadat Hashemi, E
Khorsand Ahmadi, M
Morteza Naghib, S
Sinha, N
Tel, J
Eslami Amirabadi, H
Den Toonder, JMJ
Majidzadeh-A, K
Item Type: Journal Article
Abstract: Introduction The information derived from the number and characteristics of circulating tumor cells (CTCs), is crucial to ensure appropriate cancer treatment monitoring. Currently, diverse microfluidic platforms have been developed for isolating CTCs from blood, but it remains a challenge to develop a low-cost, practical, and efficient strategy. Objectives This study aimed to isolate CTCs from the blood of cancer patients via introducing a new and efficient micropillar array-based microfluidic chip (MPA-Chip), as well as providing prognostic information and monitoring the treatment efficacy in cancer patients. Methods We fabricated a microfluidic chip (MPA-Chip) containing arrays of micropillars with different geometries (lozenge, rectangle, circle, and triangle). We conducted numerical simulations to compare velocity and pressure profiles inside the micropillar arrays. Also, we experimentally evaluated the capture efficiency and purity of the geometries using breast and prostate cancer cell lines as well as a blood sample. Moreover, the device’s performance was validated on 12 patients with breast cancer (BC) in different states. Results The lozenge geometry was selected as the most effective and optimized micropillar design for CTCs isolation, providing high capture efficiency (>85 %), purity (>90 %), and viability (97 %). Furthermore, the lozenge MPA-chip was successfully validated by the detection of CTCs from 12 breast cancer (BC) patients, with non-metastatic (median number of 6 CTCs) and metastatic (median number of 25 CTCs) diseases, showing different prognoses. Also, increasing the chemotherapy period resulted in a decrease in the number of captured CTCs from 23 to 7 for the metastatic patient. The MPA-Chip size was only 0.25 cm2 and the throughput of a single chip was 0.5 ml/h, which can be increased by multiple MPA-Chips in parallel. Conclusion The lozenge MPA-Chip presented a novel micropillar geometry for on-chip CTC isolation, detection, and staining, and in the future, the possibilities can be extended to the culture of the CTCs.
Issue Date: 1-May-2023
Date of Acceptance: 7-Aug-2022
URI: http://hdl.handle.net/10044/1/99106
DOI: 10.1016/j.jare.2022.08.005
ISSN: 2090-1232
Publisher: Elsevier BV
Start Page: 105
End Page: 121
Journal / Book Title: Journal of Advanced Research
Volume: 47
Copyright Statement: Ó 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Publication Status: Published
Online Publication Date: 2022-08-11
Appears in Collections:Bioengineering
Faculty of Engineering



This item is licensed under a Creative Commons License Creative Commons